Showing results (291-300 of 531) with videos related to
Sort By:
Pageof 54
Journal of the American College of Cardiology|August 10, 2000
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for StentL Cho, E J Topol, C Balog, et al.Circulation|July 12, 2001
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularizationA M Lincoff, D J Kereiakes, M A Mascelli, et al.Proceedings of the National Academy of Sciences of the United States of America|December 15, 2020
Allosteric cooperation in a de novo-designed two-domain proteinFabio Pirro, Nathan Schmidt, James Lincoff, et al.Journal of the Endocrine Society|February 6, 2025
Testosterone Replacement Therapy and Risk of COVID-19 and Effect of COVID-19 on Testosterone's Treatment EffectKarol M Pencina, A Michael Lincoff, Eric A Klein, et al.Journal of Clinical Lipidology|February 12, 2025
Characteristics and outcomes of patients with and without statin-associated muscle symptoms treated with bempedoic acid in the CLEAR Outcomes trialUlrich Laufs, A Michael Lincoff, Stephen J Nicholls, et al.American Heart Journal|July 11, 2006
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trialVivek Rajagopal, A Michael Lincoff, David J Cohen, et al.Circulation|April 1, 1998
Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial InvestigatorsD J Kereiakes, A M Lincoff, D P Miller, et al.Circulation|June 3, 1998
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG InvestigatorsN S Kleiman, A M Lincoff, D J Kereiakes, et al.Pharmacoeconomics|January 19, 2026
Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT TrialMartin Bøg, Anders Bo Bojesen, Scott Emerson, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCAZachary S Yaker, A Michael Lincoff, Leslie Cho, et al.Pageof 54